A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Abstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian...

Full description

Bibliographic Details
Main Authors: Wenna Guo, Liucun Zhu, Minghao Yu, Rui Zhu, Qihan Chen, Qiang Wang
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Clinical Epigenetics
Subjects:
OSC
Online Access:http://link.springer.com/article/10.1186/s13148-018-0574-0
id doaj-926a04dd4d11439e9ec7aae3fcd420c5
record_format Article
spelling doaj-926a04dd4d11439e9ec7aae3fcd420c52020-11-24T23:55:58ZengBMCClinical Epigenetics1868-70751868-70832018-11-0110111010.1186/s13148-018-0574-0A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinomaWenna Guo0Liucun Zhu1Minghao Yu2Rui Zhu3Qihan Chen4Qiang Wang5State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversitySchool of Life Sciences, Shanghai UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversitySchool of Life Sciences, Shanghai UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityAbstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers. Conclusions This five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.http://link.springer.com/article/10.1186/s13148-018-0574-0BiomarkerDNA methylationOSCPrognosisRisk stratification
collection DOAJ
language English
format Article
sources DOAJ
author Wenna Guo
Liucun Zhu
Minghao Yu
Rui Zhu
Qihan Chen
Qiang Wang
spellingShingle Wenna Guo
Liucun Zhu
Minghao Yu
Rui Zhu
Qihan Chen
Qiang Wang
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
Clinical Epigenetics
Biomarker
DNA methylation
OSC
Prognosis
Risk stratification
author_facet Wenna Guo
Liucun Zhu
Minghao Yu
Rui Zhu
Qihan Chen
Qiang Wang
author_sort Wenna Guo
title A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
title_short A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
title_full A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
title_fullStr A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
title_full_unstemmed A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
title_sort five-dna methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
publisher BMC
series Clinical Epigenetics
issn 1868-7075
1868-7083
publishDate 2018-11-01
description Abstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers. Conclusions This five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.
topic Biomarker
DNA methylation
OSC
Prognosis
Risk stratification
url http://link.springer.com/article/10.1186/s13148-018-0574-0
work_keys_str_mv AT wennaguo afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT liucunzhu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT minghaoyu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT ruizhu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT qihanchen afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT qiangwang afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT wennaguo fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT liucunzhu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT minghaoyu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT ruizhu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT qihanchen fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
AT qiangwang fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma
_version_ 1725460373257060352